Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -548.74% is 228% below its 5-year average of -167.09%, near the low end of its 5-year range (-548.74%–0.00%).
58.39% below its 12-month average of -346.44%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -126.40%.
RETURN ON ASSETS (ROA)
-548.74%
RETURN ON ASSETS (ROA) AVG TTM
-346.44%
RETURN ON ASSETS (ROA) AVG 3Y
-242.08%
RETURN ON ASSETS (ROA) AVG 5Y
-167.09%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-58.39%
CURRENT VS 3Y AVG
-126.67%
CURRENT VS 5Y AVG
-228.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.70%
median of 715 covered companies
CURRENT VS SECTOR MEDIAN
-1687.43%
vs the sector median at left
Estrella Immunopharma, Inc.
Market Cap
$18.41M
Return on Assets (ROA)
-548.74%
TTM Avg
-346.44%
3Y Avg
-242.08%
5Y Avg
-167.09%
Market Cap
$19.86M
Return on Assets (ROA)
-393.39%
TTM Avg
-225.59%
3Y Avg
-343.91%
5Y Avg
-343.91%
Market Cap
$19.66M
Return on Assets (ROA)
-15.04%
TTM Avg
-19.94%
3Y Avg
-19.35%
5Y Avg
-18.92%
Market Cap
$19.14M
Return on Assets (ROA)
-188.98%
TTM Avg
-90.06%
3Y Avg
-67.42%
5Y Avg
-51.71%
Market Cap
$20.92M
Return on Assets (ROA)
-173.14%
TTM Avg
-158.95%
3Y Avg
-120.45%
5Y Avg
-102.27%
Market Cap
$18.86M
Return on Assets (ROA)
-64.55%
TTM Avg
-0.45%
3Y Avg
-55.72%
5Y Avg
-45.67%
Market Cap
$21.68M
Return on Assets (ROA)
-228.73%
TTM Avg
-145.44%
3Y Avg
-152.25%
5Y Avg
-187.73%
Market Cap
$17.63M
Return on Assets (ROA)
-39.68%
TTM Avg
-29.52%
3Y Avg
-26.86%
5Y Avg
-20.28%
Market Cap
$17.36M
Return on Assets (ROA)
-30.06%
TTM Avg
65.41%
3Y Avg
-56.95%
5Y Avg
-76.50%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | $18.41M | -548.74% | -346.44% | -242.08% | -167.09% |
| Actuate Therapeutics Inc (ACTU)vs › | $19.86M | -393.39% | -225.59% | -343.91% | -343.91% |
| P3 Health Partners Inc. (PIII)vs › | $19.66M | -15.04% | -19.94% | -19.35% | -18.92% |
| NextCure, Inc. (NXTC)vs › | $19.14M | -188.98% | -90.06% | -67.42% | -51.71% |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.92M | -173.14% | -158.95% | -120.45% | -102.27% |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.86M | -64.55% | -0.45% | -55.72% | -45.67% |
| Modular Medical, Inc. (MODD)vs › | $21.68M | -228.73% | -145.44% | -152.25% | -187.73% |
| Cosmos Health Inc. (COSM)vs › | $17.63M | -39.68% | -29.52% | -26.86% | -20.28% |
| PAVmed Inc. (PAVM)vs › | $17.36M | -30.06% | 65.41% | -56.95% | -76.50% |
| LeonaBio, Inc. (LONA)vs › | $22.63M | -248.63% | -139.76% | -97.50% | -68.94% |
ROA
-548.7%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -411.19% |
| 2024-12-31 | -281.70% |
| 2024-06-30 | -164.15% |
| 2022-12-31 | -111.29% |
| 2022-06-30 | -34.24% |
| 2021-06-30 | 0.00% |
